Eli Lilly

Eli Lilly is a pharmaceutical company that develops and markets drugs, including treatments for obesity such as Zepbound and retatrutide.

Why it’s in the news: It is in the news due to clinical trial results, legal actions against the black market for its drugs, and expanded access programs for its obesity treatments.

Latest on Eli Lilly

• STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
• STAT+: Eli Lilly targets booming black market for retatrutide
• Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
• STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
• STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
• Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads
• 13F: S&A Financial Services holds Eli Lilly ($390,593)
• 13F: First National Bank Of Mount Dora Trust Investment Services holds Eli Lilly ($12M)
• 13F: Paragon Capital Management holds Eli Lilly ($1M)
• 13F: Intelligence Driven Advisers Llc holds Eli Lilly ($838,883)
• 13F: Stokes Capital Advisors Llc holds Eli Lilly ($11M)
• 13F: Kessler Investment Llc holds Eli Lilly ($3M)

Connections

57 entities linked to Eli Lilly across the news graph.